

## **HHS Public Access**

Author manuscript

Contemp Clin Trials. Author manuscript; available in PMC 2021 March 01.

Published in final edited form as: Contemp Clin Trials. 2020 March ; 90: 105936. doi:10.1016/j.cct.2020.105936.

## Corrigendum to Rationale and design of the <u>S</u>tudy <u>to</u> <u>U</u>nderstand Fall <u>R</u>eduction and vitamin <u>D</u> in <u>Y</u>ou (STURDY): A randomized clinical trial of Vitamin D supplement doses for the prevention of falls in older adults

Erin D. Michos, MD, MHS<sup>1,2,3</sup>, Christine M. Mitchell, ScM<sup>2,3</sup>, Edgar R. Miller III, MD, PhD<sup>2,3,4</sup>, Alice L. Sternberg, ScM<sup>2</sup>, Stephen P. Juraschek, MD, PhD<sup>3,4,5</sup>, Jennifer A. Schrack, PhD<sup>2,3,6</sup>, Sarah L. Szanton, PhD<sup>6,7,12</sup>, Jeremy D. Walston, MD<sup>6,8</sup>, Rita R. Kalyani, MD, MHS<sup>2,6,9</sup>, Timothy B. Plante, MD, MHS<sup>10</sup>, Robert H. Christenson, PhD<sup>11</sup>, Dave Shade, JD<sup>2</sup>, James Tonascia, PhD<sup>2</sup>, David L. Roth, PhD<sup>6,8</sup>, Lawrence J. Appel, MD, MPH<sup>2,3,4</sup>, STURDY Collaborative Research Group

<sup>1</sup> Division of Cardiology, Johns Hopkins School of Medicine, Baltimore, MD

<sup>2</sup> Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

<sup>3</sup>Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University, Baltimore, MD

<sup>4</sup> Division of General Internal Medicine, Johns Hopkins School of Medicine, Baltimore, MD

<sup>5</sup> Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA

<sup>6</sup>.Center on Aging and Health, Johns Hopkins University, Baltimore, MD

<sup>7</sup> Johns Hopkins School of Nursing, Baltimore, MD

<sup>8</sup> Division of Geriatric Medicine and Gerontology, Johns Hopkins School of Medicine, Baltimore, MD

<sup>9</sup> Division of Endocrinology, Diabetes, and Metabolism, Johns Hopkins School of Medicine, Baltimore, MD

<sup>10.</sup>Department of Medicine, Larner College of Medicine at the University of Vermont, Burlington, VT

<sup>11.</sup>Department of Pathology, University of Maryland Medical Center, Baltimore, MD

<sup>12.</sup>Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

We have identified two errors in our article:

<sup>&</sup>lt;u>Correspondence</u>: Erin D. Michos, MD, MHS, FACC, FAHA, Division of Cardiology, Johns Hopkins School of Medicine, Blalock 524-B, 600 N. Wolfe Street, Baltimore, MD 21287, Telephone: 410-502-6813, Fax: 410-502-0231, edonnell@jhmi.edu. <u>Clinical Trial Registration</u>: NCT02166333

1) misstatement of the primary analysis plan: the primary analysis plan is the intention-totreat comparison of the pooled non-control doses group versus control with time to primary outcome measured from randomization for all participants, not the analysis which compares experience on best dose versus control dose. The primary analysis was stated correctly in our statistical analysis plan developed at the start of the trial. Importantly, this correction is not a protocol change; rather, the description of primary analysis in the design paper incorrectly stated what we had pre-specified in our statistical analysis plan.

2) inconsistent use of the term "best dose": the "best dose" is the non-control dose identified during dose-finding stage as best at preventing the primary outcome; in some sentences, "best dose" was used incorrectly to denote the pooled non-control doses group.

We regret the confusion caused by our errors.